Literature DB >> 22124789

The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis.

Richard Charles John Campbell1, Michael Batley, Anthony Hammond, Fowzia Ibrahim, Gabrielle Kingsley, David L Scott.   

Abstract

We investigate a range of clinical factors and anti-rheumatic treatments, for their degree of association with rheumatoid arthritis (RA) fatigue in 557 patients. A range of clinical measures concerning disability, pain and disease activity together with drug history were recorded as part of routine clinical visits. Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT-F) questionnaire. Spearman's correlation (p < 0.05) evaluated FACIT-F against the other clinical measures. Mean FACIT-F was compared between the treatment groups. Multivariate linear regression analysis investigated association between the clinical measures and FACIT-F in more detail. Correlation (p < 0.05) with FACIT-F was the strongest for Health Assessment Questionnaire (HAQ) (r = -0.68), patient global (r = -0.64) and pain (r = -0.62) visual analogue scores. In multivariate models, DAS28, HAQ and pain explained variability in fatigue the best (R(2) = 0.54). Further analyses, looking at the sub components of DAS28, show that fatigue is mainly associated with tender joint counts and pain rather than swollen joint counts or erythrocyte sedimentation rate. RA fatigue levels were not significantly different between patients on no treatment, disease modifying anti-rheumatic drugs or biologics. Fatigue in established RA is not specifically influenced by the type of treatment used but is associated with tender joint counts, pain and disability. This finding is in contrast to recent trials in early RA that suggest biologics are better than traditional disease modifying anti-rheumatic drugs for fatigue. This difference in result may be because the origins of fatigue are not the same in early compared with established RA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124789     DOI: 10.1007/s10067-011-1887-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Authors:  Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw
Journal:  Arthritis Rheum       Date:  2006-05

2.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

3.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.

Authors:  David Cella; Susan Yount; Mark Sorensen; Elliot Chartash; Nishan Sengupta; James Grober
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

4.  Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis.

Authors:  John R Kirwan; Sarah Hewlett
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

5.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

6.  The prevalence and meaning of fatigue in rheumatic disease.

Authors:  F Wolfe; D J Hawley; K Wilson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

7.  Predictors of subjective fatigue among individuals with rheumatoid arthritis.

Authors:  B A Huyser; J C Parker; R Thoreson; K L Smarr; J C Johnson; R Hoffman
Journal:  Arthritis Rheum       Date:  1998-12

8.  Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.

Authors:  S Yount; M V Sorensen; D Cella; N Sengupta; J Grober; E K Chartash
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

9.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors:  Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  17 in total

1.  Neuromuscular fatigue is weakly associated with perception of fatigue and function in patients with rheumatoid arthritis.

Authors:  Rafaela Cavalheiro do Espírito Santo; Marcelo Gava Pompermayer; Rodrigo Rico Bini; Vanessa Olszewski; Elton Gonçalves Teixeira; Rafael Chakr; Ricardo Machado Xavier; Claiton Viegas Brenol
Journal:  Rheumatol Int       Date:  2017-11-27       Impact factor: 2.631

2.  Disease activity and fatigue in juvenile idiopathic arthritis.

Authors:  Sarah Ringold; Teresa M Ward; Carol A Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

3.  Sociodemographic factors associated with functional disability in outpatients with rheumatoid arthritis in Southwest China.

Authors:  Shangping Zhao; Yanling Chen; Hong Chen
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

4.  Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.

Authors:  Emilie Lund Egsmose; Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2015-05-19       Impact factor: 2.980

5.  Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.

Authors:  Kyeong Min Son; Sung Yeon Lee; Young Il Seo; Ji-Eun Choi; Hyun Ah Kim
Journal:  Clin Rheumatol       Date:  2017-04-27       Impact factor: 2.980

6.  Role of Sleep Disturbance, Depression, Obesity, and Physical Inactivity in Fatigue in Rheumatoid Arthritis.

Authors:  Patricia Katz; Mary Margaretten; Laura Trupin; Gabriela Schmajuk; Jinoos Yazdany; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

7.  Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic.

Authors:  Ole Rintek Madsen; Eva Marie Egsmose
Journal:  Rheumatol Int       Date:  2016-07-23       Impact factor: 2.631

8.  Evaluating the consequences of rheumatoid arthritis.

Authors:  Björn Sossong; Stefan Felder; Malte Wolff; Klaus Krüger
Journal:  Eur J Health Econ       Date:  2016-07-28

9.  Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice.

Authors:  Ganesh V Halade; Paul J Williams; Jyothi M Veigas; Jeffrey L Barnes; Gabriel Fernandes
Journal:  Exp Biol Med (Maywood)       Date:  2013-06

10.  What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?

Authors:  Francisco Amparo; Yiping Jin; Pedram Hamrah; Debra A Schaumberg; Reza Dana
Journal:  Am J Ophthalmol       Date:  2013-09-21       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.